Common Contracts

EX-10.2 4 d189769dex102.htm EX-10.2 CD19 LICENSE AGREEMENT EXECUTION VERSION LICENSE AGREEMENT by and among JUNO THERAPEUTICS, INC. and CELGENE CORPORATION and CELGENE SWITZERLAND LLC Dated as of April 22, 2016

License Agreement • May 5th, 2020

• Contract Type
  License Agreement
• Filed
  May 5th, 2020

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

LICENSE AGREEMENT by and among JUNO THERAPEUTICS, INC. and CELGENE CORPORATION and CELGENE SWITZERLAND LLC Dated as of April 22, 2016

License Agreement • August 5th, 2016 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances)

• Contract Type
  License Agreement
• Filed
  August 5th, 2016
• Company
  Juno Therapeutics, Inc.
• Industry
  Biological products, (no disgnostic substances)

This LICENSE AGREEMENT (this “License Agreement”) is entered into and made effective as of April 22, 2016 (the “License Agreement Effective Date”) by and among Juno Therapeutics, Inc., a Delaware corporation (“Juno”), and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations under this License Agreement in the United States, and Celgene Switzerland LLC (“Celgene Switzerland”), with respect to all rights and obligations under this License Agreement outside of the United States, (Celgene Switzerland and Celgene Corp. together, “Celgene”). Celgene and Juno are each referred to herein as a “Party” or, collectively, as the “Parties.”